Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

Trontinemab is one of a class of new medicines aimed at clearing amyloid plaques. The new findings from phase two trials ...

Researchers find that tiny doses of lithium could slow Alzheimer’s symptoms by reducing brain plaques and protecting neural ...

People with Alzheimer’s disease have lower levels of lithium in their brains than those without cognitive impairment, and the ...

In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months ...

The drug is called Leqembi, and it removes plaques in the brain that are associated with Alzheimer's. After about 18 months, ...

Groundbreaking new Alzheimer’s treatment could give patients four years of better health. Patients who participated in the ...

A NEW “game-changing” drug could stop the progression of Alzheimer’s disease, early trials suggest. Scientists say the ...

Eli Lilly & Biogen's Alzheimer's drugs may offer minimal impact despite aggressive marketing. Click here to get insights on ...

The wildfire smoke that blanketed Michigan this summer and part of 2023 could take a toll on Michiganians long after clearing, medical experts said.

Patients could have four more years of good health on the new drug while trial users have seen cognitive improvements too ...

Donanemab, approved by the FDA in 2024 to treat Alzheimer's disease, is a monoclonal antibody directed at N-terminally ...